Complete-PsA

Canadian Active Drug Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis

Brief summary

The current study will assess the real - life effectiveness of an active drug in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).

Observational

Observational study

Status:
Completed
Conditions:
Psoriatic Arthritis
Enrollment:
483 patients
Protocol ID:
P12-666
Observational model:
Cohort
Time perspective:
Prospective

 

Eligibility criteria

Participant attributes:
Male and Female

Age:

From 18 Years to 99 Years.

Inclusion Criteria:

- Adult >= 18 years old

- Has provided written informed consent allowing the use of their data for the study and
providing permission for contact by the study personnel

- Active Psoriatic Arthritis (PsA) with three (3) or more tender and swollen joints as
well as active psoriatic skin lesions or confirmed history of psoriasis

- Inadequate response or non-tolerant to current disease-modifying antirheumatic drugs
(DMARD) based treatment for PsA

Exclusion Criteria:

- Currently participating in another prospective study including controlled clinical
trials and observational studies

- Patient cannot or will not sign informed consent

- Stable disease with adequate tolerance and response to current treatment and no change
in treatment is indicated

- Previous treatment with anti-tumor necrosis factor (anti-TNF) or other biologic agent

All the cities where the clinical studies are located

Burlington - L7L 0B7

More information about this study

clinicaltrials.gov